Mednet Logo
CommunityNeurology

How do you counsel B cell-depleted multiple sclerosis patients on the benefits of regular COVID-19 vaccinations?

In light of immunogenicity data of three-dose COVID-19 vaccines (Shawe-Taylor et al., PMID 41425831).
4 Answers
Mednet Member
Mednet MemberInvited Expert
Neurology · University of Ottawa
Answered on

The fact that B cell-depleted patients render a blunted antibody response is not unexpected, but antibodies do not protect from viral infections - cells do. To measure a proper vaccine response, one wants to test T cells from patients to see if they are able to kill viral infected cells. This is wha...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Neurology · Icahn School of Medicine at Mount Sinai
Answered on

I tell patients that they should stay current with recommended COVID-19 vaccinations. I counsel them that even though they may not have a robust humoral response to the vaccine, they still get some protection, as T cell responses are preserved. And the risk of the vaccine is minimal.

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Neurology · University of South Alabama
Answered on

Same thoughts as below. We discuss that antibody response to the vaccine is likely reduced, but preserved cellular immunity helps to fill the gap.

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Neurology · University of Kentucky
Answered on

While anti-CD20 drugs may not influence innate and CD8 T cell responses, the effect of prolonged suppression of the humoral responses following with a fixed dosing schedule needs to be revisited. No prospective study has compared a scheduled, fixed dosing regimen of anti-CD20 medications to a ‘test’...

Join for free or sign in to see the full answer